Tirzepatide is a new class of medication for t2d that activates GIP and glp1 receptors. Endocrinologist Dr. Thomas Blevins (MD, FACE) from Texas Diabetes and Endocrinology, Austin, TX, presents data and practical information for clinicians.
Tirzepatide is a new class of medication for t2d that activates GIP and glp1 receptors. Endocrinologist Dr. Thomas Blevins (MD, FACE) from Texas Diabetes and Endocrinology, Austin, TX, presents data and practical information for clinicians.
Tirzepatide Once Weekly for the Treatment of Obesity (2022) Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Sean Wharton, M.D., Pharm.D., Lisa Connery, M.D., Breno Alves, M.D., Arihiro Kiyosue, M.D., Ph.D., Shuyu Zhang, M.S., Bing Liu, Ph.D., Mathijs C...
The type 2 diabetes drug tirzepatide has been reported to induce weight loss in patients with diabetes. A new randomized trial reports weight loss with tirzepatide in patients without diabetes. These findings are summarized in a short video.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.